Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions
GlomerulonephritisMembranous NephropathyantiPLA2R Positive
Interventions
DRUG

MOR202

MOR202 will be administered as an intravenous infusion

Trial Locations (25)

Unknown

Managadze National Center of Urology, Tbilisi

Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi

University Hospital Aachen, Aachen

Charite, Berlin

DaVita Clinical Research, Düsseldorf

Uniklinikum, Essen

Hospital of Johannes Gutenberg University, Mainz

General Hospital of Athens, Athens

General Hospital of Heraklion Venizeleio-Papaneio, Heraklion

University General Hospital of Patras, Pátrai

General Hospital of Thessaloniki, Thessaloniki

Botkin Hospital Moscow, Moscow

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

Hallym University Sacred Heart Hospital, Chuncheon

JeJu National University Hospital, Jeju City

Konkuk University Hospital, Seoul

Kyung Hee University Hospital at Gangdong, Seoul

Seoul National University Bundang Hospital, Seoul

Chang Gung Memorial Hospital, Kaohsiung City

Shuang Ho Hospital, New Taipei City

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Taiwan University Hospital, Taipei

Kings College, London

Nottingham Renal and Transplant Unit, Nottingham

All Listed Sponsors
lead

HI-Bio, A Biogen Company

INDUSTRY

NCT04733040 - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) | Biotech Hunter | Biotech Hunter